Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Go back to Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study| (NASDAQ: CNTB) | Delayed: 2.12 +0.03 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.09 | 52 Week High | $ | |||
| Open | $2.10 | 52 Week Low | $ | |||
| Day High | $2.18 | P/E | N/A | |||
| Day Low | $2.04 | EPS | $ | |||
| Volume | 311,675 | |||||
